Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;67(1):241-251.
doi: 10.1007/s10620-021-06836-3. Epub 2021 Feb 3.

Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study

Jasmijn Z Jagt  1 , Christine D Pothof  2 , Hans J C Buiter  3 , Johan E van Limbergen  4 , Michiel P van Wijk  2   4 , Marc A Benninga  4 , Nanne K H de Boer  5 , Tim G J de Meij  2   4
Affiliations

Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study

Jasmijn Z Jagt et al. Dig Dis Sci. 2022 Jan.

Abstract

Background: In the recent era of growing availability of biological agents, the role of thiopurines needs to be reassessed with the focus on toxicity.

Aims: We assessed the incidence and predictive factors of thiopurine-induced adverse events (AE) resulting in therapy cessation in pediatric inflammatory bowel disease (IBD), related to thiopurine metabolites and biochemical abnormalities, and determined overall drug survival.

Methods: We performed a retrospective, single-center study of children diagnosed with IBD between 2000 and 2019 and treated with thiopurine therapy. The incidence of AE and overall drug survival of thiopurines were evaluated using the Kaplan-Meier method. Correlations between thiopurine metabolites and biochemical tests were computed using Spearman's correlation coefficient.

Results: Of 391 patients with IBD, 233 patients (162 Crohn's disease, 62 ulcerative colitis, and 9 IBD-unclassified) were prescribed thiopurines (230 azathioprine and 3 mercaptopurine), of whom 50 patients (22%) discontinued treatment, at least temporary, due to thiopurine-induced AE (median follow-up 20.7 months). Twenty-six patients (52%) were rechallenged and 18 of them (70%) tolerated this. Sixteen patients (6%) switched to a second thiopurine agent after azathioprine intolerance and 10 of them (63%) tolerated this. No predictive factors for development of AE could be identified. Concentrations of 6-thioguanine nucleotides (6-TGN) were significantly correlated with white blood cell and neutrophil count, 6-methylmercaptopurine (6-MMP) concentrations with alanine aminotransferase and gamma-glutamyltranspeptidase.

Conclusions: Approximately 20% of pediatric patients with IBD discontinued thiopurine treatment due to AE. A rechallenge or switch to mercaptopurine is an effective strategy after development of AE. Concentrations of 6-TGN and 6-MMP are associated with biochemical abnormalities.

Keywords: Adverse events; Inflammatory bowel disease; Metabolites; Pediatrics; Thiopurines.

PubMed Disclaimer

Conflict of interest statement

NdB has served as a speaker for AbbVie and MSD and has served as consultant and principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) research grant from Dr. Falk, TEVA Pharma BV, MLDS and Takeda. JvL reports consulting, travel and/or speaker fees and research support from AbbVie, Janssen, Nestlé Health Science, Novalac, Pfizer, Merck, P&G, GSK, Illumina, Otsuka. JJ, CP, HB, MvW, MB, and TdM have nothing to declare.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve of patients with IBD who developed AE leading to therapy cessation. The X-axis represents the time in months. The Y-axis represents the probability of discontinuing treatment due to AE. The cumulative incidence of AE was 13.5%, 16.7%, 17.3%, and 21.8% at 3, 6, 12, and 24 months of therapy, respectively
Fig. 2
Fig. 2
Kaplan–Meier curve of ongoing thiopurine use in the patients who tolerated thiopurine therapy. The Y-axis represents the percentage of patients still using thiopurines at different time points. The percentage of patients still using thiopurines was 97.8%, 92.0%, 84.3%, 69.2%, and 37.0% at 3, 6, 12, 24, and 60 months following initiation, respectively
See this image and copyright information in PMC

References

    1. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8:1179–1207. doi: 10.1016/j.crohns.2014.04.005. - DOI - PubMed
    1. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–291. doi: 10.1097/mpg.0000000000002035. - DOI - PubMed
    1. Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:298–305. doi: 10.1093/ecco-jcc/jjx149. - DOI - PubMed
    1. Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011;106:981–987. doi: 10.1038/ajg.2010.493. - DOI - PubMed
    1. Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn's disease. Inflamm Bowel Dis. 2011;17:2138–2143. doi: 10.1002/ibd.21612. - DOI - PubMed

MeSH terms